197 related articles for article (PubMed ID: 21629038)
61. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.
Dimri M; Bommi PV; Sahasrabuddhe AA; Khandekar JD; Dimri GP
Carcinogenesis; 2010 Mar; 31(3):489-95. PubMed ID: 19969553
[TBL] [Abstract][Full Text] [Related]
62. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
63. EZH2 depletion blocks the proliferation of colon cancer cells.
Fussbroich B; Wagener N; Macher-Goeppinger S; Benner A; Fälth M; Sültmann H; Holzer A; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2011; 6(7):e21651. PubMed ID: 21765901
[TBL] [Abstract][Full Text] [Related]
64. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
[TBL] [Abstract][Full Text] [Related]
65. EZH2 promotes proliferation and invasiveness of prostate cancer cells.
Bryant RJ; Cross NA; Eaton CL; Hamdy FC; Cunliffe VT
Prostate; 2007 Apr; 67(5):547-56. PubMed ID: 17252556
[TBL] [Abstract][Full Text] [Related]
66. Laser capture microdissection of pancreatic ductal adeno-carcinoma cells to analyze EzH2 by Western Blot analysis.
Qazi AM; Aggarwal S; Steffer CS; Bouwman DL; Weaver DW; Gruber SA; Batchu RB
Methods Mol Biol; 2011; 755():245-56. PubMed ID: 21761309
[TBL] [Abstract][Full Text] [Related]
67. Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer.
Lei YM; Zu YF; Wang J; Bai S; Shi YF; Shi R; Duan J; Cui D; Chen J; Xiang Y; Dong J
Med Oncol; 2015 Jan; 32(1):387. PubMed ID: 25428391
[TBL] [Abstract][Full Text] [Related]
68. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.
Borbone E; Troncone G; Ferraro A; Jasencakova Z; Stojic L; Esposito F; Hornig N; Fusco A; Orlando V
J Clin Endocrinol Metab; 2011 Apr; 96(4):1029-38. PubMed ID: 21289264
[TBL] [Abstract][Full Text] [Related]
69. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells.
Cai K; Wan Y; Sun G; Shi L; Bao X; Wang Z
Oncol Rep; 2012 Dec; 28(6):2101-6. PubMed ID: 22972404
[TBL] [Abstract][Full Text] [Related]
70. RBM15-Mediated N6-Methyl Adenosine (m6A) Modification of EZH2 Drives the Epithelial-Mesenchymal Transition of Cervical Cancer.
Wang R; Tan W
Crit Rev Eukaryot Gene Expr; 2024; 34(5):15-29. PubMed ID: 38842201
[TBL] [Abstract][Full Text] [Related]
71. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.
Liu T; Liu Y; Bao X; Tian J; Liu Y; Yang X
PLoS One; 2013; 8(9):e75864. PubMed ID: 24086649
[TBL] [Abstract][Full Text] [Related]
72. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
Zhang H; Chen S; Niu G; Jiang H; Yao S
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
[TBL] [Abstract][Full Text] [Related]
73. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
74. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
Karanikolas BD; Figueiredo ML; Wu L
Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
[TBL] [Abstract][Full Text] [Related]
75. Osteopontin promotes EZH2 expression and tumor progression in nasopharyngeal carcinoma.
Ma R; Luo X; Feng S; Li J; Fan Y; Wen W; Li H
ORL J Otorhinolaryngol Relat Spec; 2014; 76(5):273-81. PubMed ID: 25471249
[TBL] [Abstract][Full Text] [Related]
76. Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b.
Zhang S; Zhang G; Liu J
APMIS; 2016 Aug; 124(8):649-58. PubMed ID: 27272214
[TBL] [Abstract][Full Text] [Related]
77. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis.
Liu Y; Liu T; Bao X; He M; Li L; Yang X
Int J Gynecol Pathol; 2014 May; 33(3):218-24. PubMed ID: 24681730
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
[TBL] [Abstract][Full Text] [Related]
79. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Takawa M; Masuda K; Kunizaki M; Daigo Y; Takagi K; Iwai Y; Cho HS; Toyokawa G; Yamane Y; Maejima K; Field HI; Kobayashi T; Akasu T; Sugiyama M; Tsuchiya E; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
Cancer Sci; 2011 Jul; 102(7):1298-305. PubMed ID: 21539681
[TBL] [Abstract][Full Text] [Related]
80. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
